Inamed Corporation (Nasdaq:IMDC), a global health care company, today announced senior staff appointments for its Research and Development and its Regulatory Affairs departments. Cary Reich, PhD, has joined the company as the director of the restructured Research and Development department. The R&D department has been consolidated under the direction of Dr. Patricia Walker, Chief Science Officer. Dr. Reich most recently served as President of Calhoun Vision and, prior to that position, served as Vice President of Fusion Medical Technologies and as Vice President of R&D with Chiron Vision Corporation.

"Dr. Reich brings with him a wealth of knowledge and 25 years of experience in the development and commercialization of medical devices and pharmaceuticals. We are delighted to have Cary on our team," said Nick Teti, Chairman, President and Chief Executive Officer of Inamed. "We have restructured our research and development activities to establish a more intensive scientific infrastructure which supports our investment in and development of our product pipeline."

Additionally, Deepak Chadha has been appointed as a Senior Director, Regulatory Affairs. "Deepak is a regulatory affairs professional with the ability to manage complex submissions and projects," added Teti. "He is well versed in developing preclinical and clinical content for commercial products into formal submissions to domestic and international regulatory authorities. Today's announcements reflect our continued emphasis on investment in our product development portfolio."

Before joining Inamed, Mr. Chadha was employed at Biomeasure Incorporated as a Senior Manager, Regulatory Affairs.

About INAMED Corporation

Inamed (Nasdaq:IMDC) is a global healthcare company with over 25 years of experience developing, manufacturing and marketing innovative, high-quality, science-based products. Current products include breast implants for aesthetic augmentation and for reconstructive surgery; a range of dermal products to treat facial wrinkles; and minimally invasive devices for obesity intervention, including the LAP-BAND(R) System for morbid obesity. The Company's website is www.Inamed.com.

Forward-Looking Statements

This press release contains, in addition to historical information, forward-looking statements. Inamed is providing this information as of November 18, 2004, and expressly disclaims any duty to update information contained in this press release.

Forward-looking statements in this press release include, without limitation, express and implied statements regarding Inamed's product research and development and regulatory affairs. These forward-looking statements involve risks and uncertainties which could cause actual results to differ materially from those expressed or implied here. Readers are referred to the documents filed by Inamed with the Securities and Exchange Commission, specifically the most recent reports which identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements.

By including any information in this press release, Inamed does not necessarily acknowledge that disclosure of such information is required by applicable law or that the information is material.